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1. INTRODUCTION
A tablet is a pharmaceutical dosage form. It comprises a mixture of active
substances and excipients, usually in powder form, pressed or compacted from a
powder into a solid dose. The excipients can include diluents, binders or granulating
agents,  glidants (flow aids) and lubricants to ensure efficient tableting ; disintegrants
to promote tablet break-up in the digestive tract; sweeteners or  flavours to enhance
taste; and pigments to make the tablets visually attractive. A polymer coating is often
applied to make the tablet smoother and easier to swallow, to control the release rate
of the active ingredient, to make it more resistant to the environment (extending its
shelf life), or to enhance the tablet's appearance.
1.1 Properties of tablets:
The attributes of an acceptable tablets are as follows:
· The  tablet must be sufficiently strong and resistance to shock and abration and
to withstand handling during manufacturing, packing, shipping and use.
Hardness and friability tests measure this property.
· Tablet must be uniform in weight and in drug content of the individual tablet.
This is measured by the weight variation and content uniformity tests.
· The drug content of the tablet must be bioavailable. This property is measured
by dissolution test. Accurate bioavailability can be obtained from the drug
levels of the drug after administration.
· Tablets must be elegant in appearance and must have characteristic shape,
color, and other markings necessary to identify the product.
· Tablets must retain all these functional attributes, which include drug stability
and efficacy.
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1.2 Advantages of tablets
· They are easy to administered
· They are a unit  dosage form, and they offer the greater capabilities of  all oral
dosage  forms  for the greatest dose precision and the least content variability
· Their cost is lowest of oral dosage forms
· They are the lightest and most compact of all oral dosage forms
· Product identification  is potentially the simplest and cheapest, requiring no
additional processing steps when employing an embossed or monogrammed
punch face
· They are in general the easiest and cheapest to package and ship of all oral
dosage forms
· They may provide the greatest ease of swallowing with the least tendency for
“hang-up” above the stomach. Especially when  coated ,provided the tablet
disintegration is not excessively rapid
· They lend themselves to certain special release profile products, such as enteric
or delayed release product.
· They are better suited to large-scale production than other unit oral forms
· They have the best-combined properties of chemical, mechanical and
microbiological  stability of all oral forms.
· One of the major advantages of tablet over capsules is that the tablet is
essentially “tamperproof dosage form”.
1.3 Disadvantages  of Tablets
· Some drugs resist compression into dense compacts, owing to their amorphous
nature or flocculent, low-density character.
· Drug with poor wetting, slow dissolution properties, intermediate to large
dosages, optimum absorption high in the gastrointestinal tract, or any
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combination of these features may be difficult or impossible to formulate and
manufacture as a tablet that will still provide adequate or full drug
bioavailability.
· Bitter taste drugs with objectionable odour or drugs that the sensitive to oxygen
or atmosphere moisture may require encapsulation or a special type of coating
which may increase the most of the finished tablets.
· A major disadvantage of capsules over tablets is their higher cost.
 1.4 Types of tablets
 Tablets are classified according to their route of administration or function.
The following are the four main classification groups
 1.4.1 Tablets ingested orally
· Compressed tablets
· Multiple compressed tablets
· Multi layered tablets
· Sustained action tablets
· Enteric coated tablets
· Sugar coated tablets
· Film coated tablets
· Chewable tablets
a)Compressed tablets:
These tablets are an uncoated and made by compression of granules. These
tablets are usually intended to provide rapid disintegration and drug release in the
stomach, and its drug contents are absorbed in the gastrointestinal tract and distribute
in whole body.
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b)Multiple compressed tablets(MCT):
These tablets are prepared to separate physically or chemically incompatible
ingredients or to repeat  action prolonged action products .To avoid incompatibility,
the ingredients of the formulation except the incompatible materials are compressed
into a tablet then incompatible substance along with necessary excipients are
compressed as tablets.
c)Multilayered tablets:
These tablets consists of two or more layer of materials compressed
successively in the same tablets. The color of each layer may be same or different.
The tablets having  layers are of different colors are known as “Multicolored tablets”
d)Sustained action  tablets:
These tablets are used to get a sustained action of medicament. These tablets
when taken orally release the medicament in a sufficient quantity as and when
required maintaining the maximum effective concentration of the drug in the blood
throughout the period of treatment.
e)Enteric-coated tablets:
These are compressed tablets meant for administration by swallowing and are
design to by ass the stomach and get disintegrated in the intestine only. These tablets
are made to release drug undiluted and in the highest concentration possible in the
intestine eg. The tablets containing antihelmenthics and amoebiacides.
f)Sugar coated tablets(SCT):
The compressed tablets having a sugar coating are called “sugar coated
tablets”. Such coating may colored and are beneficial in covering up drug substances
processing objectionable tests or odors and protecting materials sensitive to oxidation.
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g)Film coated tablets(FCT):
These are compressed tablets that are covered with a thin layer or a film of
water soluble materials. A number of polymeric substances with film forming
properties may be used. Film coating imparts the same general characteristics as sugar
coating, with the added advantage of greatly reduced time period required for the
coating operation and reduced thickness of coating, these compressed tablets having
some polymer substances, such as hydroxyl propyl cellulose, hydroxyl propyl methyl
cellulose.
h)Chewable tablets:
These tablets are chewed in the mouth and broken into small pieces. In this
way, the disintegration time is reduced as the rate of medicament is increased. E.g:
aluminum hydroxide tablets, phenolphthalein tablets.
i)Buccal tablets
These tablets are to be placed in the buccal mouth or between the gums and lips
or cheek where they dissolve or disintegrate slowly and are absorbed directly without
passing into the alimentary canal. e.g: tablets of  Ethisterone.
j)Sublingual  tablets
These tablets are to be placed under the tongue where they dissolve or
disintegrate quickly and are absorbed directly without passing into GIT. E.g: Tablets
of glyceryltrinitrites,
k)Lozenges and Torches
These tablets are designed to external local effect in the mouth or throat .These
tablets are commonly used to treat sore throat or to control coughing in common cold.
They may contain local anaesthetics, antibacterial agents, astringent and antitussives.
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l)Implantation tablets
These tablets are placed under the skin or inserted  subcutaneous by means of
minor surgical operation and are slowly absorbed .These implants must be sterile and
should be packed individually in sterile condition .Impants are mainly used for
administration of hormone such as testorone, and deoxycorticosterone  etc.
m)Vaginal tablets
These tablets are meant to dissolve slowly in the vaginal cavity.These tablets
are typically ovoid or pear shaped to facilitate retention steroids,antibacterial
agents,antiseptics, or astringents to treat  vaginal infections.
n)Effervescent tablets
In addition to the drug substance, these contain sodium bicarbonate and an
organic acid such as tartaric acid or citric acid. In the presence of water, these
additives react, liberating carbon dioxide that acts as disintegrator and produces
effervescence. Except for small quantities of lubricants present, effervescent are
soluble.
o)Hypodermic tablets
These are soft, readily soluble tablets and originally were used for the
preparation of solutions to be injected. Since stable parental solutions are now
available for most new drug substances, there is no justification for the hypodermic
tablets for injection. Their use in this manner should be discouraged, since the
resulting solution are  no sterile. Large quantities of these tablets continue to be made,
but for oral administration. No hypodermic tablets ever have been recognized by the
official compendia.
1.4.2 Tablets used in the oral cavity
· Buccal tablets
· Subingual tablets
· Lozenge tablets
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· Trouches
· Dental cones
1.4.3 Tablets administered by other routes
· Implantation tablets
· Vaginal tablets
1.4.4 Tablets used to prepare solutions
· Effervescent tablets
· Molded tablets or  tablet triturates (TT)
· Dispensing tablets(DT)
· Hypodermic tablets(HT)
1.5 Excipients:
Pharmaceutical dosage forms contain both pharmacologically active
compounds and excipients added to aid the formulation and manufacture of the
subsequent dosage form for administration to patients. Indeed, the properties of the
final dosage form (i.e. its bioavailability and stability) are, for the most part highly
dependent on the excipient choosen, their concentration and interaction with both the
active compound and each other.
Excipients are inert substances used as diluents or vehicles for a drug. In the
pharmaceutical industry it is a catch all term which includes various sub groups
comprising diluents or fillers, binders or adhesives, disintegrants, lubricants, glidants
or to flow promoters, colors, flavors, fragrances and sweetners.
Tablet excipients must meet certain criteria information as follows:
· They must be physiologically inert
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· They must be acceptable to regulatory agencies
· They must be physically & chemically stable by themselves and in
combination with the drugs and other tablet  component.
· They must be free of any bacteria considered to be pathogenic or otherwise
objectionable.
· They must not interfere with the bioavailability of the drug.
· They must be commercially available in form & purity commensurate to
pharmaceutical standards.
· For drug products that are classified as food, such as vitamins, other dietary
aids, and so on, the excipients must be approved as food additives.
· Cost must be relatively inexpensive.(Lachmann  L.,et al.,1991)
1.6 Tablet Manufacturing
a)  Dispensing (Weighing and measuring)
Dispensing is the first step in any pharmaceutical manufacturing process.
Dispensing is one of the most critical steps in pharmaceutical manufacturing: as
during this step, the weight of each ingredient in the mixture is determined according
to dose.
Dispensing may be done by purely manual by hand scooping from primary
containers and weighing each ingredient by hand on a weigh scale ,manual weighing
with material lifting assistance like vacuum transfer and bag filters ,manual or assisted
lifting of  loss-in weight dispensing system ,automated dispensaries with mechanical
devices such as vacuum loading system and screw feed system.
Issues like weighing accuracy ,dust control (laminar flow booths, glove
boxes),during manual handling, lot control of each ingredient ,material movement in
and out of dispensery should be considered during dispensing.
INTRODUCTION
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Fig .1 Various Unit operation sequences in Tablet Manufacturing
b) Manufacturing of powder blend
In the tablet pressing process the main guideline is to ensure that the
appropriate amount of active ingredient is in each tablet .Hence, all the ingredients
should be well –mixed .If a sufficiently homogenous mixture of the components
cannot be obtained with simple blending processes, the ingredients must be granulated
prior to compression to assure an even distribution of the active compound in the final
tablet. Two basic techniques are used to granulate powders for compression into a
tablet. :wet granulation and dry granulation. Powders that can be mixed well do not
require granulation and can be compressed into tablets through direct compression.
ACTIVE
INGREDIENT
EXCIPIENTS
MIXING AND
GRANULATION
     DRYING
COMPRESSION
COATING
PACKAGING
INTRODUCTION
 10
c)Granulation techniques:
1) Direct compression
The method consists of compressing tablets directly from powdered
material without modifying the physical nature of the material itself  .Direct
compression method of tablet making is of special interest for small group of
crystalline chemicals having all the physical characteristics necessary for the
formulation of a good tablet .Examples include chloride , chlorate, bromide ,iodine,
nitrate, ammonium chloride which posses cohesive and flow properties that makes
direct compression possible .Tablets in this category are usually intended to provide
rapid disintegration and drug release.
Some of the advantages of this method are simplicity of the process
,absence of granulating step, avoidance of moisture and drying steps, minimum
material handling ,and rapidity of total process and optimum bioavailability of the
drug.
2)Wet granulation
Wet granulation is a process of using a liquid binder to lightly
agglomerate the powder mixture .The amount of liquid has to be properly
controlled,as over-wetting  cause the granules to be too hard and under –wetting will
cause them to be too soft and friable .Aqueous solutions have the advantage of being
faster to deal with an solvent –based systems.
Procedure:
Step 1: The active ingredient  and excipients are weighed and mixed.
Step 2: The wet granulate is prepared by adding the liquid binder  - adhesive  to the
powder blend and mixing thoroughly. Examples  of binders /adhesives include
INTRODUCTION
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aqueous preparations of cornstarch ,natural gums such as acasia ,cellulose derivatives
such as methyl cellulose and povidone .
Step 3: Screening the damp mass through mesh to fom pellets or granules.
Step 4:Drying the granulation .A  conventional tray-dryer or fluid-bed dryer are most
commonly used.
Step 5 : After the granules are dried ,they are passed through a screen of smaller size
than the one used for the wet mass to create granules of uniform size.
Low shear wet granulation process use very simple equipment ,and can take a
considerable time to achieve a uniformly mixed state .High shear wet granulation
process use equipment that mixes the powder and liquid at a very fast rate. Fluid bed
granulation is a multiple-step wet granulation process performed in the same vessel to
pre-heat ,granulate ,and dry the powders.
3)Dry granulation
Dry granulation process is also known as ‘slugging’, ‘double compression’ or
‘recompression’ method. This process can be used when the tablet ingredient are
sensitive to moisture or are unable to withstand elevated temperature during drying.
Essential steps in this method include weighing, mixing, slugging, dry screening,
lubrication and compression.
Dry granulation process creates new granules by light compaction of the
powder blend under low pressures.The compacts so formed are broken up gently to
produce granules(agglomerates).This process is often used when the product to be
granulated is sensitive to moisture and heat .Dry granulation can be conducted on a
tablet press using slugging tooling or on a roll press called a roll compacter.
Dry granulation equipment offers a wide range of  pressures to attain proper
densification and granule formation. Dry granulation is simpler than wet granulation
,therefore the cost is reduced .However ,dry granulation often produces a higher
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percentage of fine granules, which can compromise the quality or create yield
problems  for the tablet .Dry granulation requires drugs or excipients with cohesive
properties ,and a ‘dry binder’ may need to be added to the formulation to facilitate the
formation of granules.
d)Granules lubrication
After granuation, a final lubrication step is used to ensure that the tableting
blend does not stick to the equipment during the tableting process. This usually
involves low shear blending of the granules with a powdered lubricant, such as
magnesium stearate  or stearic acid.
e)Compression
After preparation of the granules (in case of wet granuation) or sized slugs (in
case of dry granulation) or mixing of ingradients (in case of direct compression), they
are compressed to get final product. The compression is done either by single punch
machine (stamping press) or by multi station machine.(rotary press).
The tablet press is a high speed mechanical device. It ‘squeezes’ the ingredients
into the required tablet shape with extreme precision. It can make the tablet in many
shapes, although they are usually round or oval. Also, it can press the name of the
manufacturer or the product into the top of the tablet. Each tablet is made by pressing
the granules inside a die, made up of hardened steel. The die is a disc shape with a
hole cut through its centre. The powder is compressed in the centre of the die by two
hardened steel punches that fit into the top and bottom of the die.
The punches and dies are fixed to a turret that spins round. As it spins, the
punches are driven together by two fixed cams – an  upper cam and lower cam. The
top of the upper punch (the punch head) sits on the upper cam edge. The bottom of the
lower punch sits on the lower cam edge.
The shapes of the two cams determine the sequence of movements of the two
punches. This sequence is repeated over and over because the turret is spinning round.
The force exerted on the ingredients in the dies is very carefully controlled. This
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ensures that each tablet is perfectly formed. Because of the high speeds, they need
very sophisticated lubrication systems. The lubricating oil is recycled and filtered to
ensure a continuous supply7,8
1.7 Common stages occurring during compression:
Stage 1:
Top punch is withdrawn from the die by the upper cam bottom punch is low in the die
so powder falls in through the hole and fills the die.
Stage 2:
Bottom  punch moves up to adjust the powder weight-it raises and expels some
powder.
Stage 3:
Top punch is driven into the die by upper cam bottom punch is raised by lower cam .
Both punch heads  pass between heavy rollers to compress the powder
Stage  4:
Top punch is withdrawn by the upper cam lower punch is pushed up and expels the
tablet. Tablet is removed from the die surface by surface plate.
Stage 5: Return to stage 1.(Lachmann  L.,et al.,1989)
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1.8 MINI-TABLETS:
Mini-tablets are small tablets with a diameter typically equal to or less than 2.5
mm that are typically filled into a capsule, or occasionally, further compressed into
larger tablets. It is possible to incorporate many different mini-tablets, each one
formulated individually and programmed to release drug at different sites within the
gastrointestinal tract, into one capsule. These combinations may include immediate
release, delayed release, and/or controlled release mini-tablets. It is also possible to
incorporate mini-tabs of different drugs to treat concurrent diseases or combinations
of drugs to improve overall therapeutic outcome, while delivering distinct release rates
of each according to disease requirements.
1.8.1 Advantages:
Mini-tablets combine the advantages of multiparticulate dosage forms with the
established manufacturing techniques of tableting.
Ø Mini-tablets include excellent size uniformity, regular shape and a smooth
surface, thereby offering an excellent substrate for coating with modified
release polymeric systems.
Ø There is a less  risk of dose dumping, less inter and intra-subject variability,
high degree of dispersion in the digestive tract thus minimising the risk of high
local drug concentrations.
Ø Mini tablets also offer an alternative for pellets because of their relative ease of
manufacturing and because dosage form of equal dimensions and weight with
smooth regular are produced in a reproducible and continuous way.
Mini-tablets can be produced via direct compression and can be manufactured
using conventional tableting machines with only minor equipment modifications. For
example, in order to increase production speeds, multiple-tip tooling has been
employed routinely. Furthermore mini-tabs can be coated using either a perforated
coating pan or a fluid bed apparatus(Brabander C.,2000).
Literature Review
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2.LITERATURE REVIEW
Goole J ,et al., relates to the development and the in vitro evaluation of sustained-
release minitablets (MT), prepared by melt granulation and subsequent compression
which are designed to float over an extended period of time. Levodopa was used as a
model drug. The importance of the composition and manufacturing parameters of the
MT on their floating and dissolution properties was then examined. The investigation
showed that MT composition and MT diameter had the greatest influence on drug
release, which was sustained for more than 8 h. By using the  formulation, the best
floating properties were obtained with 3mm MT prepared at low compression forces
ranging between 50 and 100 N. Their resultant-weight (RW) values were always
higher than those obtained with a marketed HBS dosage form within 13 h.By
evaluating the dissolution profiles of levodopa at different pH values, it was found that
dissolution profiles depend more on the prolonged-release ability of Methocel®
K15M than on the pH-dependent solubility of levodopa. Finally, the robustness of the
floating MT was assessed by testing the drug release variability in function of the
stirring conditions during dissolution tests.
Gohel  M and  Saraviya K, formulated the enteric mini tablets of isoniazid by cold
extrusion method. The mini tablets were prepared by using isoniazid ,HPMC phthalate
and dibasic calcium phosphate .Mini tablets were coated using HPMC phthalate.The
drug release were resisted in 0.1N HCL for 2hrs from the optimized batch.It showed
more than 90% of drug release in phosphate buffer  in 15min .Capsules containing
rifampicin powder and enteric isoniazid mini tablets showed complete drug release in
acidic and alkaline media respectively.(Gohel M and  Saraviya  K,2010).
Paresh Prajapati  A .et al., prepared Ocular minitablets (MT) of diclofenac sodium
by single punch compression machine equipped with 4mm flat round tooling specially
developed in the lab. Invivo release of drug from ocular MT was determined in
rabbit’s eye and invitro release rate of drug was determined at different dissolution
volume and rotational speed. Three invitro methods were used for the determination
of  drugs and their release from various ophthalmic preparations by using Static
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method, Stirred (paddle) method and Rotating Vial method. . Finding correlation co-
efficients and plotting a scatter diagram established invitro-invivo relationship. The
Rotating vial method matched best with invivo results Specific hydrodynamic and
volume showed high invitro-invivo correlation. The work identified a suitable invitro
method of drug release from Ocular minitablets (MT). (Paresh Prajapati A.,et al.2010)
Shiva kumar Y,et al.  investigated  Sumatriptan Nasal Mucoadhesive Minitablets
using different mucoadhesive polymers Chitosan,Carbopol 971P and Gum copal along
with Methocel. Mucoadhesive minitablets of Sumatriptan were prepared by direct
compression method. The minitablets were evaluated for thickness, hardness, swelling
index, mucoadhesion and in vitro drug release. All postcompressional parameters
were found to be within acceptable standard limits. It was observed that mucoadhesive
minitablets contained polymer blend of Carbopol, Carbopol/ Chitosan , Carbopol/
Gum copal were successfully controlled the release of drug up to 7 days. Optimum
formulation was obtained based on evaluation studies.(Shiva kumar Y,et al.2010)
Seyed Alireza,et al. studied the preparation and evaluation of ciprofloxacin-
containing minitablets for ocular use, in an attempt to obtain prolonged and controlled
drug release to the anterior eye segment  Following initial studies on ciprofloxacin
powder, it was formulated into ocular mini tablets For this purpose, ciprofloxacin
along with various amounts of mini tablets  different sustained release cellulose
derivatives  (HPMC, Na CMC, HEC and EC),  Carbopol 974P, solubilizer and
lubricant were directly  compressed  into minitablets, using concave 3 mm diameter
punches.All the prepared formulations were evaluated in terms of physicochemical
tests, including uniformity of weight, friability, crushing strength, water uptake and
in-vitro drug release studies.It was found that the type and amount of cellulose
derivatives used, can influence the rate of drug release..The  selected formulation
contained ethyl cellulose, Carbopol 974P, mannitol, sodium stearyl fumarate and
ciprofloxacin, which showed more than 80% drug release over a period of 5h, and
complied well in all the physicochemical tests conducted.(Seyed Alireza,et al.2009)
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Lingam M.,et al.   developed a  gastro retentive floating drug delivery system with
multiple-unit minitab’s based on gas formation technique  in order to prolong the
gastric residence time and to increase the overall bioavailability of the drug. The
system consists of the drug-containing core units prepared by direct compression
process, which are coated with three successive layers of an inner seal
coat,effervescent layer (sodium bicarbonate) and an outer gas-entrapped polymeric
membrane of an polymethacrylates (Eudragit RL30D, RS30D, and combinations of
them). Only the system using Eudragit RL30D and combination of them as a gas-
entrapped polymeric membrane could float. The time to float decreased as amount of
the effervescent agent increased and coating level of gas-entrapped polymeric
membrane decreased. The optimum system floated completely within 3 min and
maintained the buoyancy over a period of 12 h. Increasing coating level of gas-
entrapped polymeric membrane decreased the drug release. Both the rapid floating
and the controlled release properties were achieved in the multiple-unit floating drug
delivery system developed in this present study. The analysis of the parameter
dissolution data after storage at 40 °C and 75% RH for 3 months showed, no
significant change indicating the two dissolution profiles were considered to be
similar (f2 value is more than 50).(Lingam .,et a.2008)
Shiva  kumar  HN,et al. studied  pH-sensitive tablet in capsule system which
intended to approximate the chronobiology of nocturnal asthma is proposed for site
specific release to the colon. The system comprising of Eudragit S-100 coated
minitablets was designed for chronotherapeutic delivery of theophylline in view to
specifically target the nocturnal peak symptoms of asthma. The drug-loaded core
minitablets were produced by wet granulation procedure using alcoholic solution of
PVP K 30 as a binder. Different coat weights of Eudragit S-100 were applied to the
drug loaded core minitablets in a conventional coating pan to produce the pH sensitive
minitablets. . In vitro dissolution studies performed following pH progression method
demonstrated that the drug release from the coated minitablets depended on the coat
weights applied and pH of the dissolution media. The studies showed that a coat
weight of 10% weight gain was sufficient to impart an excellent gastro resistant
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property to the tablets for effective release of the drug at higher pH values.(Shiva
kumar  HN,et al.2007).
         Aim and Objective
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3. AIM AND OBJECTIVE
OBJECTIVE:
Psychosis  is  a  special  type  of  mental  disorder  that  effects  about  2-3% of  the
global   population  and  has  a  strong  genetic  basis.  Group of diseases are present
such as schizophrenia, bipolar disorder, major depressive disorder. The conventional
tablet may be difficult to take by the patient without missing the dose and it’s also
produced more side effects due to high dose. It is necessary to choose alternative
dosage forms for the treatment of psychosis with better patience compliance. The best
alternative dosage forms may be Extended Release Risperidone Minitablets.
Minitablets may enhance oral absorption due to more surface area and also possible to
extended release of the drug. Mini tablets are smaller and it can be filled in to the hard
gelatin capsules. The system has specific advantages over conventional single unit
dosage forms. The advantage of the system include low risk of dose dumping, less
intra and inter variability and high degree of dispersion in the digestive tract thus
minimizing the risk of high local drug concentration .Extended release minitablets
systems are capable of providing the desired concentration of the drug plasma levels
over an extended period of time within the therapeutic range.
The main objective of the present study is to develop Extended Release Mini tablets of
Risperidone using cellulose polymers like HPMC as release modifiers in the form of
mini tablets filled in ‘1’ size hard gelatin capsule. The drug and excipients
         Aim and Objective
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compatibility are studied with different ratios. Characterisation of minitablet is carried
out by using uniform content, hardness, weight variation, friability. In-vitro
dissolution study is carried out in pH 6.8 Phosphate buffer as a dissolution medium.
Kinetic models are applied to the release data to find out the release mechanism.
Plan of Work
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4. PLAN   OF   WORK
· To collect the relevant literature regarding the drug
· .Study of the drug and excipients compatibility.
· To prepare different   formulations  of  Risperidone   minitablets.
· To evaluate physical properties of minitablets like thickness, hardness,
friability etc.
· To evaluate the in-vitro drug release of minitablets.
· Filling of  best  formulation of   Risperidone mini tablets in capsule.
· To evaluate the physical parameters of the capsule.
Drug & Excipent Profile
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5. DRUG & EXCIPIENT PROFILE
Name of Drug Risperidone
Chemical Name
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)1-
piperidinyl]ethyl]-    6,7,8,9-tetrahydro- 2-methyl-4H-
pyrido[1,2-a]pyrimidin-4-one.
Formula C23H27FN4O2
Structure
Physicochemical properties
Molecular Mass 410.49.gm/mol
Description White to slightly beige powder.
Solubility
Insoluble in water, freely soluble in methylene
chloride and soluble in methanol and 0.1N HCL.
Pharmacology
Category Antipsychotic
Dose 2-4mg/day.
Dosage form Mini tablets filled in hard gelatin capsules.
Storage
Stored below 300c in dry place and protected from
light.
Drug & Excipent Profile
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MECHANISM  OF ACTION
Risperidone is an antipsychotic of the benzisoxazol derivatives.It is a selectve
monoaminergic antagonist.Risperidone has affinity for serotonin5HT2,dopamine-
D2,H1-histamine,alpha1-and alpha2-adrenergic receptors.Risperidone has no affinity for
cholinergic receptors.It is a potent D2-antagonist.
Pharmacokinetics
Risperidone is rapidly and very well absorbed after oral administration.Peak
plasma concentrations are attained within 1-2hrs.Risperidone is 90% plasma protein
bound.It is metabolized by cytochrome P-450 IID6 to 9-hydroxy-risperidone.The
Elimination half-life was found to be about 3-20hrs.
The pharmacokinetic characteristics are given in below table.1
Pharmacokinetic characters
Oral bioavailability 70%(oral)
Plasma protein binding 90%
Metabolism Hepatic
Excretion Urinary
Elimination t1/2 (hr) 3-5hrs
Routes of administration Oral
Drug & Excipent Profile
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INDICATIONS:
     Risperidone  is indicated in the treatment of :
     a) acute and chronic schizophrenic psychosis and related psychosis.
     b)Behavioural disturbances in patients with dementia.
CONTRAINDICATIONS:
1. Risperidone is contra-indicated in patients   with known  sensitivity to the
medicine.
2. Women receiving Risperidone should not breast feed.
3. Not for children under 5 years as  efficacy and safety in children under 5
years have not been demonstrated.
PRECAUTIONS:
· Patients are advised not to drive as risperidone may impair mental alertness.
· Dose should be reduced to halve in geriatric and patients with renal or liver
insufficiency
· Hypotension may occur during initial dose titration period due to alpha
blocking activity, dose reduction should be considered during hypotension
· Parkinson disease patients should be cautious while taking  risperidone.
DRUG INTERACTIONS:
Risperidone should be used with caution in combination with alcohol and other
centrally acting medicines. It may antagonize the effect of levodopa and other
dopamine agonist
Carbamazepine has been shown to decrease the plasma levels of the active
antipsychotic fraction of risperidone
Drug & Excipent Profile
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Tricyclic anti depressants, phenothiazines, and beta blockers may increase the plasma
concentration of risperidone.
ADVERSE EFFECTS:
Risperidone has been associated with weight gain, akathisia, sedation, dysphoria,
insomnia,  sexual dysfunction, low blood pressure, high blood pressure, muscle
stiffness, muscle pain, tremors, increase salivation, constipation
Risperidone can potentially cause neuroleptic malignant syndrome (NMS)
Risperidone may also trigger diabetes and more serious conditions of glucose
metabolism, including ketoacidosis and hyperosmolar com.
Drug & Excipent Profile
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EXCIPIENT PROFILE
Hydroxy propyl methyl cellulose
Chemical name Cellulose 2- hydroxy propyl methyl ether
Synonym Cellulose, Hypromellose, 2 – Hydroxypropylmethyl
ether, Methyl hydroxy propyl cellulose, Methocel,
Pharmacoat, Metolose.
Description It is a white, yellowish white or grayish white,
practically odorless, fibrous powder or granules.
Solubility Soluble in cold water, forming a colloidal solution,
practically insoluble in hot water, dehydrated alcohol,
chloroform and ether.
pH A 1% w/w solution has a pH of 5.5 - 8.0
Melting point Browns at 190-2000C, chars at 225-2300C, Tg is at
170-1800C
Autoingnition temperature 3600C
Bulk density 0.341 gm/cm3
Tapped density 0.557 gm/cm3
Gel formation Undergoes a reversible transformation from solution to
gel upon heating and cooling respectively.
Gel point 50 – 900C depending upon the grade
Ash value 1.5 – 3 % depending upon the grade
Specific gravity 1.3
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Surface activity Provides some surfactancy in solutions, surface tension
for such solutions range from 42 – 56 dynes/cm.
Table 2. Typical viscosity values for 2% (w/v) aqueous solutions of methocel
(Dow Chemical Co.). viscosities measured at 20°C
Incompatibilities: Hypromellose is incompatible with some oxidizing agents. Since it
is nonionic, hypromellose will not complex with metallic salts or ionic organics to
form insoluble precipitates.
Safety: Hydroxypropyl methylcellulose is generally regarded as a nontoxic and
nonirritant material although excessive oral consumption may have a laxative effect.
Pharmaceutical uses: HPMC is widely used in oral and topical pharmaceutical
formulations. It is used as tablet binder, for film coating and in sustained release
preparations. Hypromellose is also used as a suspending and thickening agent in
topical formulations, particularly ophthalmic preparations. It is also used as an
emulsifier, suspending agent and stabilizing agent in topical gel and ointments.
[Raymond CR et al., 2003]
Methocel product
USP 28
designation
Nominal viscosity
(mPa s)
Methocel K4M Premium 2208 4,000
Methocel K15M Premium 2208 15,000
Methocel K100M Premium 2208 100,000
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Lactose
Lactose monohydrate as a natural disaccharide, obtained from milk, which consists of
one galactose and one glucose moiety.
Synonyms Lactochem, Pharmatose, NF Lactose, Capsulac, Granulac,
Tablettose, Inhalac,  Prismalac, Sachelac
Description White to off-white crystalline particles or powder, odorless
and slightly sweet-tasting; α-lactose is approximately 20%
as sweet as sucrose, while β-lactose is 40% as sweet.
Functional Category Binding agent; diluent for dry-powder inhalers; tablet
binder; tablet and capsule diluent.
Grades Lactochem powder, coarse powder, fine powder;
Pharmatose 50M, 80M, 90M, 100M, Inhalac 70, 120, 230;
Lactose monohydrate NF 80M.
Solubility Soluble in water (1 in 5.24), practically insoluble in
chloroform, ethanol and ether.
Angle of repose 33° for Pharmatose DCL 15; 32° for Tablettose 70 and
Tablettose 80.
Melting point 201–202°C (for dehydrated α-lactose monohydrate)
Density (true) 1.545 g/cm3 (α-lactose monohydrate)
Safety Adverse reactions to lactose are largely attributed to lactose
intolerance, which occurs in individuals with a deficiency of
the intestinal enzyme lactase. This results in lactose being
undigested and may lead to cramps, diarrhea, distension,
and flatulence.
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Incompatibilities A Maillard-type condensation reaction is likely to occur
between lactose and compounds with a primary amine
group to form brown, or yellow-brown-colored products.
Lactose is also incompatible with amino acids,
aminophylline, amfetamines, and lisinopril.
Stability Mold growth may occur under humid conditions (80%
relative   humidity and above). Lactose may develop a
brown coloration on storage, the reaction being accelerated
by warm, damp conditions.
Storage It should be stored in a well-closed container in a cool, dry
place.
Uses Widely used as a filler or diluent in tablets and capsules, and
to a more limited extent in lyophilized products and infant
formulas. It is also used as a diluent in dry-powder
inhalation.
Drug & Excipent Profile
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Magnesium stearate
Chemical name Octadecanoic acid magnesium salt
Synonym Magnesium octadecanoate, octadecanoic acid,
magnesium salt, stearic acid, magnesium salt.
Description Magnesium stearate is a very fine, light white,
precipitated or milled, impalpable powder of low bulk
density, having a faint odor of stearic acid and a
characteristic taste. The powder is greasy to the touch and
readily adheres to the skin.
Solubility practically insoluble in ethanol, ethanol (95%), ether and
water; slightly soluble in warm benzene and warm
ethanol (95%).
Bulk density 0.159 g/cm3
Specific surface area 1.6–14.8 m2/g
Tapped density 0.286 g/cm3
Melting range 117°C –150°C
Incompatibilities Incompatible with strong acids, alkalis, and iron salts.
Avoid mixing with strong oxidizing materials.
Magnesium stearate cannot be used in products
containing aspirin, some vitamins, and most alkaloidal
salts.
Pharmaceutical uses It is primarily used as a lubricant in capsule and tablet
manufacture at concentrations between 0.25% and
5.0%w/w. It is also used in barrier creams. [Raymond CR
et al., 2003]
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Colloidal silicon dioxide
Chemical name Talc
Synonym Aerosil, Cab-O-Sil, Cab-O-Sil M-5P, colloidal silica,
fumed silica, light anhydrous silicic acid, silicic anhydride,
silicon dioxide fumed, Wacker HDK.
Description Talc is a very fine, white to grayish-white, odorless,
impalpable, unctuous, crystalline powder. It adheres readily
to the skin and is soft to the touch and free from grittiness
Solubility practically insoluble in organic solvents, water, and acids,
except hydrofluoric acid; soluble in hot solutions of alkali
hydroxide. Forms a colloidal dispersion with water
pH 3.5–5.5
Bulk density 0.029–0.042 g/cm3
Specific surface area 200–400 m2/g (Stroehlein apparatus, single point), 50–380
m2/g (BET method)
Tapped density 0.5–1.2 g/cm3
Incompatibilities Incompatible with diethylstilbestrol preparations
Pharmaceutical uses Adsorbent, anticaking agent, emulsion stabilizer (1.0–5.0
%), glidant (0.1–0.5%), tablet disintegrant, suspending
agent, thermal stabilizer and viscosity-increasing agent
(2.0–10.0 %) [Raymond CR et al., 2003].
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6. Experimental work
List of excipients and equipments
Table 3.  List of drug and materials
Sr. No. Materials Use Manufactured/Supplied by
1 Risperidone
Anti-pyschotic
agent
Kopalle Pharma chemicals
(P)Ltd
2 HPMC(K100M) polymer
Colorcon Asia Pvt. Ltd.,
Goa
3 Lactose filler Sri Jindutt Pharma .Pvt.Ltd
4
Magnesium
stearate
lubricant
S.D. fine chemicals,
Mumbai
5 Aerosil glidant
S.D. fine chemicals,
Mumbai
Table 4.  List of chemicals and reagents
Sr. No. Materials Manufactured/Supplied by
1
Potassium di hydrogen
phosphate
Thomas Baker, Mumbai
2 Sodium hydroxide AR grade Merck Limited, Mumbai
3 Hydrochloric acid Thomas Baker, Mumbai
4 Methanol Merck Limited, Mumbai
Materials and equipments
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Table 5.  List of equipments
Sr. No Name of equipment Make
1 Electronic balance Citizen Pvt. Ltd, Mumbai
2 pH meter Toshniwal Instruments, Ajmer
3 Laboratory sieves Kumar Test Sieves
4 UV-Visible spectrophotometer Shimadzu
5 Hot air oven Lab-shop corporation, Mumbai
6 Tablet compression machine Cadmach Ahmadabad
7 Monsanto hardness tester Cadmach
8 Vernier caliper Hanna Instruments
9 Roche friability tester Labhosp, Mumbai
10
Dissolution test apparatus
(six station)
Electrolab
Methodology
34
 6.1 Preformulation studies: A preformulation activity ranges from supporting
discovery’s identification of new active agents to characterizing physical properties
necessary for the design of dosage form. Critical information provided during
Preformulation can enhance the rapid and successful introduction of new therapeutics
entities for humans. Preformulation testing is an investigation of physical and
chemical properties of a drug substance.
 The overall objective of preformulation testing is to generate information useful in
developing the formulation which is stable and bio-available. Further the use of
Preformulation parameters maximizes the chances in formulating an acceptable, safe,
efficacious and stable product. For any drug substances to formulate into a dosage
form, it is necessary to study the physicochemical properties of the bulk drug like
physical appearance, solubility, bulk density, tapped density, compressibility, melting
point, molecular weight, sieve analysis.
        The following  pre-formulation studies were performed for the  Risperidone mini
tablet formulations are as follows:
a).Angle of repose:-
        Angle of  repose is defined as the maximum angle possible between the surface
of pile of powder and the horizontal plane. The granule mass should allowed to flow
out of the funnel orifice on a plane paper kept on the horizontal surface .This forms a
pile of granules on the paper.
Where,
             h= height of the pile
             r=radius of the pile
Methodology
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Table 6:Limits for angle of repose according to I.P..
SNo. Angle of  repose(a)degrees Flow
1 <25 Excellent
2 25-30 Good
3 30-40* Passable
4 40 & above Very poor
b) Bulk  density:-
    It is the ratio between a given mass of powder and its bulk volume.
Mass of powder
                   Bulk density =
                                                         Total weight of the powder
A given quantity of the powder is transferred to the measuring cylinder and it is
tapped mechanically either manually or mechanical device till a constant volume is
obtained .This  volume is bulk volume(v) and it includes the true volume of the
powder and void space among the powder particles.
c)Tapped density:-
      Tapped density is defined as the ratio between weight of the sample powder taken
and the tapped volume.
                                                   Tapped density( t)= M/Vf
Where, M= weight of sample powder taken
            Vf =  tapped volume
Methodology
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d)Hausners ratio:
By using following formula ,the Hausners ratio can be calculated.
                                                                                          Tapped density
                                                     Hausner ratio =
                                                                                         Bulk density
Table 7:Limits for Hausners ratio according to I.P.
Hausners ratio Type of  flow
Less than 1.25 Good flow
1.25-1.5 Moderate flow
More than 1.5 Poor flow
Compressability Index: It is an important measurement that can be obtained from
bulk and tapped density.
                                                          Bulk density – Tapped density
              Carr’s index = x 100
                                                              Bulk density
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Table 8:Limits for Carr’s index according to I.P.
SNo Carr’s index Properties
1
2
3
4
5
6
5-12
12-16
18-21
23-25
33-38
>40
Free flow
Good
Fair
Poor
Very poor
Extremely poor
e). Drug – Excipients compatibility study:
As a part of the product development, the compatibility of various
excipients with active was evaluated.
According to the functional category these excipients were mixed in different
ratio with drug. These mixtures were kept in 40°C / 75 %RH, and 60°C, in a 2-ml
glass vial in exposed condition for 1 month. Excipients are mixed with the drug
quantity in following ratio.
At the interval of 2 weeks and 4 weeks, the samples were withdrawn and given
to analytical development for analysis of following parameters:
Ø Moisture content
Ø Assay
Methodology
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6.2Method for preparation of minitablets
Development of extended release minitablets by direct compression method
             Extended release mini tablets  were  prepared using  risperidone
,HPMCK100M, HPMCK 15M, lactose, Aerosol ,magnesium  stearate .Variable
concentration of drug polymer ratio and other  excipients are  weighed and mixed as
per formulation batches. The powder blends are  lubricated with aerosil and
magnesium stearate ,and passed through sieve no.60 and then directly compressed
using  mini punches.
Direct compression method consists of compressing tablets directly from
powdered material with out modifying the physical nature of the material. In direct
compression method the drug along  with suitable ingredients are mixed. These are
directly compressed into mini  tablets.
Main Steps Involved in the direct compression method is:
Milling of drugs and excipients
Mixing of excipients
Tablet compression
Methodology
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 Table 9: Formula  table  for  Risperidone  minitablets
S.
No
          Trial
Ingradients
   F1   F2    F3     F4    F5     F6
1 Risperidone(gms)    4    4   4  4  4   4
2 HPMCK100M
(gms)
50 37.5 75 - - 75
3 HPMCK15M - - - 75 100 -
4 Lactose (gms) 25 50 25 25 25 50
5 Aerosil(gms) 1 1  1  1 1 1
6  Magnesium
Stearate (gms)
0.5 0.5 0.5 0.5 0.5 0.5
Total (gms) 80.5  93 105.5 105.5 130.5 130.5
Methodology
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6.3   Evaluation of tablets
The important parameters in the evaluation of tablets can be divided into physical and
chemical parameters.
1.Physical appearance
The general appearance of tablets its visual identity and over all elegance is
essential for consumer acceptance. The control of  general appearance of tablet
involves measurement of number of attributes such as tablet size, shape, color
presence or absence of  odour, taste ,surface texture and consistency of any
identification marks.
2.Tablet size and thickness:
Control of physical dimensions of the tablets such as size and thickness is
essential for consumer acceptance and tablet-tablet uniformity .The diameter size  and
punch size of tablets depends on the die and punches selected for making the tablets.
The thickness of tablet is measured by Vernier Calipers scale. The thickness of the
tablet related to the tablet  hardness and can be used an initial control parameter
.Tablet thickness should be controlled within a +or -5%. In addition thickness must be
controlled to facilitate packaging.
3.Average weight of tablets:
          Take randomly 20 tablets and weigh accurately 20 tablets and calculate the
average weight.
                                                    Weight of 20 tablets
        Average weight =
                                                                     20
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4. Hardness test:-
This is the force required to break a tablet in diametric compression. Hardness
of the tablet is determined by Stock’s Mosanto hardness tester which consists of a
barrel with a compressible spring. The pointer moving along the guaze in the barrel
which the tablet fractures. Hardness of 5 kg considered as suitable for handling the
tablet.
5.Uniformity of dosage units (by weight variation method)
      Take randomly 30 tablets ,weigh collectivey and individually 30 tablets and
calculate average weight of the tablets and % assay of individual dosage units by
using formula
                                                       Assay x Individual weight
                                                    =
                                                                Average weight
6.In-Vitro drug release:
In-vitro release of the drug was determined by estimating the dissolution
profile.
Dissolution test for  Risperidone:
In-vitro drug release study was carried out using USP apparatus II at 370C±
0.50C for  12hrs, at 50rpm.0.1N HCL (pH 1.2) was used as dissolution medium for the
first 2hrs ,followed by pH  6.8 phosphate buffer  for further 10hrs. 10 ml of sample
was withdrawn after every hour and was replaced with an equal volume of fresh
dissolution medium to maintain the equilibrium. Collected samples are analysed by
UV  spectrophotometer at 280nm.
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      Parameter for dissolution test:
                Apparatus                                  : USP 1 (Basket apparatus)
                Revolution per minute : 100rpm
                Dissolution medium : 6.8 phosphate     buffer
                Temperature : 37±0.50C
                Dissolution time : 20hrs
                Sample quantity with drawn : 10ml
                Sample time interval : 1hr
Results and Discussion
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7. RESULTS AND DISCUSSION
7.1. Preformulation results of selected Drug:
7.1.1 Physical characters of  Risperidone were found as:
Table 10: Physical Characters of  Risperidone
Sr. No. Characters Inference
1. Nature Amorphous  powder
2. Color white
3. Odour Odourless
5. Melting point 170οC
6. Solubility-
    In Water
    In 1N HCl
    In 0.1N HCl
    In Methanol
    In Methylene
        chloride
Insoluble
soluble
soluble
soluble
Freely soluble
7. Loss on drying 0.5% w/w (Not more than 1.0%, determined
on 1 g by drying in an oven  at 1050C)
Results and Discussion
[Type text] Page 44
7.1.2: Calibration curve was drawn in Phosphate buffer (pH 6.8), which follows beer’s
Lambert law.
7.1.3: Assay was performed to analyze the percentage purity and was found to be
101%w/w.
  Conclusion: On the basis of the above tests, it was confirmed that the drug sample of
Risperidone can be used for further study.
7.2. Preparation of Standard calibration curves:
7.2.1 Standard calibration curves of  Risperidone:
           In   Phosphate buffer pH 6.8. The curve follows Beer’s lambert law.
Table 11: Calibration curve for Risperidone in Phosphate buffer pH 6.8 at
280nm
The standard curve  of  risperidone was obtained by taking the absorbance at
280nm,the values are shown in the table below and it shows that the values  complies
the Beer’s law.
S.no
Concentration
µg/ml
Absorbance
(280nm)
1 5 0.1781
2 10 0.3121
3 20 0.5737
4 30 0.8091
5 40 1.0998
Results and Discussion
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The standard curve of the Risperidone is plotted by taking concentration on the x-axis
and absorbance on the y-axis.
Fig:1 Standard calibration curve of  Risperidone in  Phosphate buffer at  pH 6.8
at 280nm
Table:12     Drug-exciepients compatibility ratio:-
Drug-Excipients
Combination
D:E Ratio Initial
40ºc 75%
RH(1month)
60ºc(1 month)
API alone - White to half white NCC NCC
API+HPMCK100M 1:10 White to half white NCC NCC
API+HPMCK15M 1:10 White to half white NCC NCC
API+ lactose 1:10 White to half white NCC NCC
API+Magnesium
stearate
1:5 White to half white NCC NCC
API+ Aerosil 1:5 White to half white NCC NCC
Conclusion:
There was no interaction between drug and excipients. So the selected excipients
were found compatible with Risperidone.
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Table 13. Preformulation parameters of powder blend
The Risperidone powder blend was evaluated for bulk density, tapped density, angle
of repose, Carr’s ratio and Hausner ratio. The results for Risperidone are shown in the
table 13.
Formulation
Code
Bulk
density(g/ml)
Tapped
density(gm/ml)
Angle of
reposeº
Carr’s
index (%)
Hausner
ratio
F1 0.526 0.612 26.76 14.0 1.16
F2 0.662 0.763 27.54 13.23 1.15
F3 0.695 0.823 24.65 15.5 1.18
F4 0.782 0.869 28.68 11.0 1.11
F5 0.560 0.631 24.68 11.25 1.12
F6 0.628 0.714 25.16 14.27 1.17
Conclusion:
               Powder blends for mini tablets were showed Angle of repose in the range of
24065' -28068', Carr’s index less than 15.5 and Hausner ratio less than 1.18. Results
indicate that good flow properties of the powder blends were found.
Results and Discussion
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        Table 14:   Parameters of Risperidone mini tablets
S.No Parameters F1 F2 F3 F4 F5 F6
1
Average weight of
tablets(mg)
80.2 92.1 104.8 104.5 129.2 129.6
2 Thickness(mm) 3.94 3.92 3.93 3.91 3.90 3.94
3 Hardness(kg/cm2) 3.58 3.52 3.47 3.32 3.20 3.38
  4
Avg Uniformity
of  content(%)
99 98.5 99.2 98.3 99.1 98.4
CONCLUSION:
Risperidone minitablets showed the average weight in the range of 80.2 mg –
129.6mg, thickness in the range of 3.90mm – 3.94mm, hardness in the range of 3.20
kg/cm2- 3.58kg/cm2 and average uniformity of content was found 98.3 – 99.2%.
In -vitro release study
Table :15 In -vitro release data of formulations F1, F2, F3, F4, F5, F6 .
Cumulative % drug release
Time in hrs
F1 F2 F3 F4 F5 F6
1 15 25 10 21 12 15
2 21 36 15 30 24 22
4 27 45 20 42 32 30
6 35 54 30 53 43 36
Results and Discussion
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8 42 68 37 65 51 45
10 55 82 50 80 60 58
12 70 82 66 92 73 74
16 85 82 80 92 88 87
20 90 83 86 93 94 94
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Fig  : 2In -vitro release data of formulations F1,F2,F3,F4,F5,F6
CONCLUSION:
In-Vitro release data of all the formulations F1, F2, F3, F4, F5, F6, were plotted by
using time (hrs) on x-axis and percentage cumulative drug release on y- axis. Among
all the formulations F1 was found to be the best formulation showing 90% drug
release at the end of 20 hrs.
Results and Discussion
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 Table 16: In -vitro release data of formulations F1
                 The percentage drug release of formulation batch F1 is shown
below :
Time in hrs % drug release
1 15
2 21
4 27
6 35
8 42
10 55
12 70
16 85
20 90
The curve for percentage release for F1 is shown in the graph given below by taking
time on x-axis and percentage drug release on y-axis.
Fig:  3  In -vitro release data of formulations F1
Results and Discussion
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Table: 17    In -vitro release data of formulations F2
  The percentage drug release of formulation batch F2 is shown below :
Time in hrs % drug release
1 25
2 36
4 45
6 54
8 66
10 82
12 82
16 82
20 83
 The curve for percentage drug release for F2 is shown in the graph given below by
taking time on x-axis and percentage drug release on y-axis
Fig:   4 In -vitro release data of formulations F2
Results and Discussion
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Table: 18    In -vitro release data of formulations F3
The percentage drug release of formulation batch F3 is shown below :
Time in hrs % drug release
1 10
2 1
4 20
6 30
8 37
10 50
12 66
16 80
20 86
The curve for percentage release for F3 is shown in the graph given below by taking
time on x-axis and percentage drug release on the y-axis.
Fig: 5   In -vitro release data of formulations F3
Results and Discussion
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Table :19    In -vitro release data of formulations F4
The percentage drug release of formulation batch F4 is shown below :
Time in hrs % drug release
1 21
2 30
4 42
6 53
8 65
10 80
12 92
16 92
20 93
The curve for percentage drug release for F4 is shown in the graph given below by
taking time on x-axis and percentage drug release on the y-axis.
Fig: 6    In -vitro release data of formulations F4
Results and Discussion
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Table: 20 In -vitro release data of formulations F5
                         The percentage drug release of formulation batch F5 is shown below :
Time in hrs % drug release
1 12
2 24
4 32
6 43
8 51
10 60
12 73
16 88
20 94
The curve for percentage drug release for F5 is shown in the graph given below by
taking time on x- axis and percentage drug release on the y-axis.
Fig: 7 In -vitro release data of formulations F5
Results and Discussion
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Table:21  In -vitro release data of formulations F6
The percentage drug release of formulation batch F6 is shown below :
Time in hrs % drug release
1 15
2 22
4 30
6 36
8 45
10 58
12 74
16 87
20 92
The curve for percentage drug release for F6 is shown in the graph given below nd by
taking time on x-axis and percentage drug release on y-axis.
Fig  :8 In -vitro release data of formulations F6
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Kinetics Study
One of the proposed mechanisms for drug release from hydrophilic matrices implies
water penetration in the matrix hydration and swelling of the polymer (with its
expansion), diffusion of the dissolved drug and erosion of gelatinous polymer layer.
Drug release from a matrix is controlled by diffusion through the polymeric matrix
obeying fick's law. The drug release mechanism is dependent on the pH, the drug and
its own polymeric support.  In   order  to  investigate  the  model  of  release  from
tablets,  the  release  data  of  selected formulations was analyzed with the following
mathematical models
                                 Zero order equation ……. Q = K0t
                                First order equation …….. In (100- Q) = InQ-K1t
                                Korsmeyer and Peppas equation …….. Q = Kp tn
Where  Q,  is  the  percent  of  the  drug  release  at  time  t  and  K0  and  Kt  are  the
constants  of  the  equations.  Kp is the constant incorporating structural and geometric
characteristic of the release device, Ks is a constant incorporating the surface volume
relation and n is the release exponent indicative of mechanism of release.
The dissolution data were examined for models of first order, zero order, Higuchi,
Korsmeyer-Peppas .
Table 22: Kinetic models of optimized batch
Release kinetics Correlation Coefficient(R2)
Zero order equation 0.970
First order equation 0.586
Higuchi(diffusion)co-efficient 0.95
Korsmeyer Peppas equation 0.718
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                            Fig :9             Zero order plot of optimized  formulation F1
                                  Fig: 10 First order plot of optimized formulation F1
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Fig :11   Higuchi (diffusion)co-efficient plot of optimized formulation F
Fig :12Korsmeyer Peppas  plot of optimized formulation F1
Results and Discussion
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CONCLUSION:
From the kinetic study of the optimized formulation F1 was shown correlation
coefficient of Zero order kinetics (R2=0.97), First order kinetics (R2=0.586), Higuchi
(R2=0.95) and Korsmeyer peppas equation (R2=0.718). Further n value of peppas
model was found 1.019. It indicates the drug release follows non fickian diffusion
mechanism.
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8. SUMMARY AND    CONCLUSION
Minitablets are small tablets with diameter equal or less than 2.5mm that are filled
into a capsule, or occasionally compressed into larger tablets. Combinations of
different modified relese minitablets like immediate release, delayed release and / or
controlled release may include in the dosage forms. It is also possible to incorporate
minitablets of different drugs to treat concurrent diseases or combinations of drugs to
improve over all therapeutic outcome, while delivering distinct release rates of each
according to disease requirements.
The present study was carried out to formulate Risperidone minitablets filled into hard
gelatin capsule for the treatment of psychotic disorder.
The precompression parameters revealed that all the 6 formulations powder blends
was found good flow property.
Risperidone is formulated with different concentration of polymers like
HPMCK100M, HPMCK15M and filler like lactose and with other excipients. A total
number of 6 formulations (F1, F2, F3, F4, F5, F6) were prepared and evaluated.
In all the formulation thickness of the tablets varies between 3.90-3.94mm and the
hardness of the optimized batch was found to be 3.18kg/cm2. No variation in the
hardness was found in the optimized formulation that showed powder blend was
uniform.
Among 6 formulations, f1, f2, f3, f6 batches were done using HPMC K100M polymer
and f4, f5 with HPMC K15M polymer using optimized quantity of lactose. The best
batch among those was found F1 because it had 90% drug release and it also sustained
its action until 20th hr.
The optimized formulation of Risperidone was filled in the capsule and evaluation
were carried out according to the I.P. procedure.
                  In conclusion Extended Release Risperidone Minitablet was prepared and
it showed improved dissolution rate of Risperidone. From the above results it can be
Summary and Conclusion
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concluded that Extended Release Minitablets of Risperidone can be used as alternative
dosage form for the treatment of psychosis patient with good patient compliance.
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